sever
acut
respiratori
syndrom
sar
emerg
guangdong
provinc
china
late
spread
countri
end
outbreak
juli
cdc
report
case
case
fatal
rate
diseas
caus
previous
unrecogn
coronaviru
sarscov
draw
experi
anim
coronaviru
vaccin
sever
vaccin
candid
develop
evalu
preclin
trial
avail
data
suggest
vaccin
base
kda
viral
spike
protein
signific
neutral
antigen
capabl
induc
protect
immun
respons
anim
absenc
clinic
case
sar
candid
vaccin
evalu
efficaci
anim
model
although
uncertain
whether
unit
state
food
drug
administr
anim
rule
would
appli
licensur
sar
vaccin
import
develop
standard
anim
model
immunolog
assay
prepar
eventu
report
summar
recommend
technic
meet
anim
model
antibodi
assay
evalu
candid
sar
vaccin
held
august
south
mimm
uk
provid
guidanc
use
anim
model
outlin
step
develop
standard
reagent
assay
immunolog
evalu
candid
sar
vaccin
sever
acut
respiratori
syndrom
sar
sever
respiratori
ill
caus
sar
coronaviru
sarscov
diseas
emerg
guangdong
provinc
china
late
spread
countri
mostli
within
asia
although
europ
north
america
also
affect
notabl
toronto
canada
epidem
final
control
juli
strict
implement
preval
sarscov
antibodi
although
histori
sarslik
diseas
sarscovlik
virus
isol
civet
raccoon
dog
homolog
human
sarscov
major
differ
found
whose
delet
suggest
repres
sign
adapt
human
four
amino
acid
residu
receptor
glycoprotein
domain
viral
spike
protein
differ
human
epidem
sarscov
strain
civet
strain
caus
differ
bind
affin
molecul
although
high
preval
sarslik
coronavirus
found
chines
horsesho
bat
great
genet
divers
make
difficult
identifi
one
might
ancestor
sarscov
decid
certainti
whether
bat
inde
anim
reservoir
viru
sarscov
infect
exhibit
wide
clinic
cours
character
mostli
fever
dyspnea
lymphopenia
lower
respiratori
infect
often
concurr
gastrointestin
symptom
includ
diarrhea
patholog
sar
patient
associ
diffus
alveolar
damag
epitheli
cell
prolifer
multinucl
giant
cell
infiltr
epitheli
macrophag
origin
suggest
syncytiumlik
format
lung
viru
recov
peripher
blood
mononuclear
cell
respiratori
secret
stool
urin
even
sweat
review
see
sar
vaccin
develop
effort
initi
rapidli
identif
etiolog
agent
even
though
immun
correl
protect
known
research
effort
identifi
protect
antigen
develop
anim
model
undertaken
parallel
effort
develop
candid
vaccin
draw
experi
anim
coronaviru
vaccin
use
sever
vaccin
strategi
includ
inactiv
viru
vaccin
purifi
subunit
vaccin
plasmid
dna
viral
vectorbas
vaccin
well
viruslik
particl
much
effort
made
identifi
appropri
anim
model
sarscov
replic
pathogenesi
sever
research
group
shown
mice
ferret
hamster
nonhuman
primat
support
replic
sarscov
vari
degre
associ
diseas
anim
model
use
evalu
candid
vaccin
common
conclus
emerg
evalu
sever
vaccin
kda
viral
spike
protein
signific
neutral
antigen
one
elicit
protect
immun
anim
model
protein
divid
two
domain
analog
coronaviru
spike
protein
ntermin
domain
contain
receptorbind
site
neutral
epitop
ctermin
domain
form
membraneanchor
stalk
region
contain
put
fusion
peptid
follow
two
heptad
repeat
predict
form
sixhelix
coiledcoil
bundl
absenc
clinic
case
sar
candid
vaccin
evalu
efficaci
anim
model
unit
state
fda
anim
rule
state
efficaci
studi
human
feasibl
vaccin
may
approv
base
anim
data
alon
provid
pathophysiolog
mechan
diseas
reason
wellunderstood
prevent
reduct
vaccin
moreov
protect
effect
vaccin
demonstr
one
anim
speci
expect
react
respons
predict
human
endpoint
anim
studi
clearli
relat
desir
benefit
human
ie
enhanc
surviv
reduct
major
morbid
data
gener
allow
select
effect
dose
human
present
time
uncertain
whether
anim
rule
would
appli
licensur
sar
vaccin
howev
import
develop
standard
anim
model
immunolog
assay
prepar
eventu
scientist
technic
meet
anim
model
antibodi
assay
evalu
candid
sar
vaccin
held
august
south
mimm
uk
discuss
mani
aspect
research
pertain
use
anim
model
vaccin
develop
includ
avail
anim
model
suitabl
variou
model
correl
protect
critic
compon
potenti
vaccin
potenti
diseas
enhanc
vaccin
anim
follow
exposur
sarscov
addit
standard
antibodi
assay
establish
intern
standard
sarscov
antibodi
also
discuss
report
endeavor
summar
recommend
meet
base
consensu
agreement
recommend
use
anim
model
given
section
correl
protect
overview
vaccin
develop
observ
pertain
potenti
diseas
enhanc
summar
follow
section
select
anim
model
vaccin
evalu
import
rememb
principl
underli
call
anim
rule
data
one
anim
speci
often
requir
anim
speci
contribut
someth
differ
understand
diseas
protect
time
singl
model
offer
direct
reproduct
seen
human
sar
patholog
includ
pneumon
alveolar
edema
diffus
alveolar
damag
dad
human
probabl
difficult
element
reproduc
anim
model
attent
also
given
reduct
viral
shed
would
like
correl
decreas
risk
spread
diseas
among
human
use
anim
model
studi
aspect
sarscov
infect
must
emphas
kinet
viral
replic
appear
resolut
patholog
find
much
rapid
anim
model
human
whichev
anim
model
employ
special
consider
given
presenc
coexist
pathogen
age
anim
rout
infect
suffici
number
time
point
larg
enough
number
anim
use
allow
statist
evalu
strain
sarscov
use
also
could
import
emphas
differ
speci
may
prove
use
studi
differ
aspect
sarscov
wherea
vaccin
antivir
may
address
mani
model
pathogenesi
best
evalu
anim
model
immunolog
tool
reagent
avail
detail
analysi
immun
respons
vaccin
includ
inbr
mice
rhesu
cynomolgu
macaqu
may
actual
worthwhil
enhanc
virul
sarscov
isol
serial
passag
anim
model
produc
challeng
viru
stock
vaccin
studi
would
elicit
reproduc
diseas
anim
highli
virul
hostadapt
viru
becom
avail
mouseadapt
monkeyadapt
sarscov
strain
demonstr
capac
vaccin
protect
challeng
virul
strain
would
provid
almost
ideal
anim
model
differ
model
may
also
need
employ
evalu
pathogenesi
versu
immunogen
pathogenesi
studi
anim
model
mortal
requir
readout
would
ideal
develop
anim
model
compar
level
mortal
seen
human
overal
includ
increas
mortal
increas
age
age
optim
result
would
demonstr
efficaci
vaccin
antivir
sarscov
anim
model
mimic
human
morbid
mortal
show
protect
without
vaccineassoci
immunopatholog
inbr
mous
strain
balbc
support
sarscov
replic
develop
pneumon
pneumonia
clinic
symptom
observ
older
balbc
mice
mous
model
suitabl
immunogen
efficaci
studi
vaccin
prolong
viral
replic
dissemin
viru
liver
spleen
accompani
patholog
seen
mice
mice
therefor
also
suitabl
studi
pathogenesi
evalu
antivir
drug
specif
pathogenfre
spf
anim
must
use
age
either
week
month
specifi
number
anim
includ
must
suffici
statist
analysi
includ
mockinfect
control
varieti
sarscov
strain
test
mice
includ
urbani
frankfurt
mouseadapt
sarscov
strain
inocul
intranas
rout
light
anesthesia
use
dose
tcid
lmous
critic
time
point
specimen
collect
day
peak
titer
postinfect
pi
quantit
virolog
day
pi
studi
interstiti
pneumon
dad
age
mice
inflat
lung
neutralbuff
formalin
day
resolut
golden
syrian
hamster
excel
anim
model
demonstr
high
level
sarscov
replic
develop
pneumon
hamster
suitabl
vaccin
efficaci
immunoprophylaxi
treatment
studi
contrast
balbc
mice
viru
detect
respiratori
tract
clear
day
pi
hamster
demonstr
longer
durat
viral
shed
upper
respiratori
tract
transient
viremia
spread
viru
liver
spleen
significantli
inflamm
respiratori
tissu
spf
anim
older
week
age
use
suffici
number
statist
analysi
studi
design
includ
mockinfect
anim
anim
hous
pair
three
experi
last
less
week
reserv
space
avail
separ
anim
case
fight
male
litterm
tend
fight
less
viru
strain
test
hamster
urbani
frankfurt
viru
administ
rout
light
anesthesia
use
dose
tcid
lhamster
outcom
efficaci
studi
quantit
virolog
prefer
quantit
pcr
patholog
studi
one
grade
patholog
none
mild
moder
sever
per
robert
et
al
critic
time
point
specimen
collect
day
pi
peak
viral
titer
clearanc
quantit
virolog
studi
day
pi
consolid
pneumon
resolut
patholog
studi
lung
evid
one
studi
ferret
support
sarscov
replic
develop
pulmonari
lesion
accord
anoth
studi
anim
remain
asymptomat
presenc
sarscov
replic
view
conflict
data
ferret
model
need
studi
determin
optim
util
vaccin
efficaci
immun
prophylaxi
studi
addit
studi
need
defin
extent
biolog
variabl
model
possibl
role
copathogen
may
contribut
variabl
observ
differ
laboratori
anim
age
month
older
use
although
well
document
consist
viral
replic
patholog
clinic
symptom
seem
observ
older
anim
anim
screen
viral
copathogen
aleutian
mink
diseas
respiratori
virus
hepat
virus
other
rout
inocul
may
iv
dose
viru
strain
suffici
ensur
reproduc
infect
anim
like
pfu
moreferret
quantit
virolog
prefer
qrtpcr
patholog
studi
recommend
appli
nonhuman
primat
studi
see
slide
share
pathologist
develop
score
system
regard
specimen
collect
respiratori
tissu
studi
need
establish
much
variat
occur
sampl
differ
lobe
lung
critic
time
point
day
pi
quantit
virolog
day
pi
patholog
studi
pneumon
nhp
support
sarscov
replic
develop
pneumon
variabl
degre
clinic
symptom
depend
upon
speci
employ
singl
nhp
speci
prefer
time
number
anim
given
studi
need
larg
enough
account
animaltoanim
variabl
sampl
anim
suffici
view
cost
experi
challeng
studi
limit
vaccin
candid
promis
use
larger
sampl
size
animalsgroup
avoid
anim
freerang
period
life
possibl
immunolog
respons
best
studi
speci
microarray
reagent
identifi
immun
compon
avail
rhesu
cynomolgu
macaqu
howev
limit
viral
replic
observ
cynomolgu
macaqu
might
disadvantag
select
speci
studi
recommend
nhp
speci
common
marmoset
african
green
monkey
agm
chlorocebu
aethiop
sabeu
countri
origin
may
play
import
role
specifi
eg
philippin
cynomolgu
macaqu
macaca
fasciculari
china
rhesu
macaca
mulatta
brazil
marmoset
callithrix
jacchu
etc
prior
experi
anim
hous
indoor
limit
exposur
potenti
copathogen
screen
parasit
strongyloid
pneumonyssu
simicola
lung
mite
possibl
viral
copathogen
retrovirus
respiratori
virus
adenovirus
sarscov
strain
test
nhp
model
cyno
pumc
rhesu
urbani
marmoset
agm
inocul
respiratori
rout
dose
pfu
morenhp
quantit
virolog
prefer
qrtpcr
patholog
studi
would
obviou
advantag
laboratori
share
patholog
slide
review
differ
pathologist
order
develop
score
system
specimen
respiratori
tissu
collect
studi
need
establish
much
variat
occur
sampl
differ
lobe
lung
done
report
african
green
monkey
agm
critic
time
point
day
pi
quantit
virolog
cynomolgu
macaqu
agm
later
day
pi
rhesu
macaqu
chines
origin
collect
tissu
histopatholog
analys
day
pi
optim
cynomolgu
macaqu
agm
later
day
pi
rhesu
macaqu
due
limit
immunolog
reagent
includ
microarray
assay
avail
research
may
limit
rhesu
cynomolgu
macaqu
data
anim
model
insuffici
consider
use
sarscov
vaccin
antivir
evalu
addit
model
four
list
section
section
would
requir
thorough
character
includ
viral
replic
data
histopatholog
analysi
sarscovinfect
mockinfect
anim
age
gender
viral
replic
histopatholog
data
new
anim
model
reminisc
least
aspect
sar
human
although
correl
protect
sar
associ
diseas
identifi
human
infect
neutral
antibodi
present
convalesc
human
serum
antibodi
sarscov
spike
protein
shown
prevent
viru
entri
neutral
viru
infect
vitro
prophylact
administ
monoclon
antibodi
passiv
transfer
sarscov
hyperimmun
sera
shown
prevent
sarscov
infect
associ
diseas
follow
sarscov
challeng
naiv
mice
hamster
monoclon
antibodi
administ
therapeut
ie
postinfect
also
shown
limit
viral
replic
reduc
associ
diseas
hamster
although
cell
mediat
immun
may
protect
role
viral
clearanc
resolut
diseas
work
anim
model
show
antibodi
alon
effect
prevent
treatment
sar
thu
mice
immun
liverecombin
vaccin
express
sarscov
spike
protein
use
rabi
viru
vesicular
stomat
viru
vsv
adenoviru
attenu
vaccinia
viru
mva
vector
well
mice
immun
dna
vaccin
express
gene
develop
neutral
antibodi
sarscov
protect
sarscov
challeng
similar
find
report
mucos
immun
hamster
agm
use
bovin
parainfluenza
viru
type
vector
express
sar
cov
gene
sever
whole
inactiv
viru
recombin
protein
candid
vaccin
also
develop
shown
elicit
neutral
antibodi
respons
provid
protect
infecti
challeng
addit
passiv
administ
sera
vaccin
anim
prevent
sarscov
infect
upon
subsequ
challeng
mice
demonstr
antibodi
induc
vaccin
confer
protect
neutral
antibodi
titer
necessari
achiev
protect
human
expos
sarscov
howev
still
known
recommend
evalu
vaccin
efficaci
futur
anim
experi
challeng
viru
administ
two
differ
timepoint
postimmun
neutral
antibodi
titer
high
later
neutral
antibodi
titer
wane
low
also
suggest
viral
titer
patholog
evalu
two
differ
time
point
specif
time
point
sampl
collect
given
anim
model
section
previou
observ
diseas
enhanc
report
human
viral
pathogen
shown
due
antibodymedi
enhanc
viru
entri
review
see
enhanc
diseas
mortal
observ
kitten
immun
infect
typei
coronaviru
felin
infecti
periton
viru
fipv
subsequ
expos
fipv
infect
aggrav
fip
appar
result
enhanc
viral
entri
macrophag
mediat
subneutr
antibodi
level
children
vaccin
inactiv
respiratori
syncyti
viru
rsv
vaccin
develop
seriou
diseas
subsequ
exposur
rsv
individu
expos
one
four
serotyp
dengu
viru
develop
sever
diseas
subsequ
infect
second
differ
serotyp
enhanc
diseas
follow
rsv
vaccin
dengu
infect
occur
differ
mechan
fipv
view
exampl
enhanc
diseas
follow
infect
vaccin
host
heighten
concern
similar
phenomenon
could
occur
sarscov
vaccin
highli
recommend
therefor
known
mechan
diseas
enhanc
observ
virus
especi
coronavirus
examin
sarscov
infect
especi
vaccin
anim
although
none
studi
date
shown
enhanc
respiratori
diseas
follow
sarscov
challeng
previous
immun
anim
studi
area
warrant
view
avail
vitro
data
antibodi
human
sarscov
isol
shown
enhanc
entri
pseudotyp
virus
express
civet
sarslik
covspik
protein
human
renal
adenocarcinoma
cell
line
enhanc
demonstr
level
entri
replic
phenomenon
seen
pseudotyp
lentivirus
express
sarscov
spike
protein
civet
sequenc
specif
pseudotyp
virus
express
spike
protein
human
sarscov
isol
also
observ
human
isol
sarscov
role
enhanc
viral
entri
observ
vitro
studi
relat
known
compon
human
diseas
infect
vivo
howev
given
sarscov
may
replic
albeit
poorli
human
pbmc
vitro
experi
look
antibodyenhanc
sarscov
replic
human
cell
eg
macrophag
bcell
perform
sever
group
studi
sarscov
infect
anim
presenc
neutral
subneutr
level
sarscov
antisera
anti
sarscov
sprotein
monoclon
antibodi
evid
enhanc
respiratori
diseas
observ
howev
foci
hepat
necrosi
note
follow
sarscov
challeng
mvasarss
immun
ferret
although
find
worrisom
sever
question
rais
regard
signific
observ
mvasarss
vaccin
use
experi
poorli
immunogen
ferret
question
whether
could
copathogen
anim
rais
also
would
import
know
observ
phenomenon
depend
mva
vector
anim
model
strongli
urg
therefor
experi
repeat
ferret
addit
experi
nonhuman
primat
hamster
look
evid
enhanc
respiratori
hepat
diseas
upon
vaccin
challeng
also
encourag
sever
candid
sar
vaccin
variou
stage
preclin
clinic
develop
develop
worldwid
china
alon
three
compani
given
regulatori
approv
clinic
evalu
candid
sar
vaccin
import
therefor
abl
compar
data
candid
vaccin
turn
requir
intern
standard
immunolog
assay
use
evalu
vaccin
accept
method
intern
standard
employ
intern
standard
allow
comparison
result
differ
laboratori
essenti
establish
intern
requir
vaccin
diagnost
therapeut
prepar
materi
bear
close
resembl
sampl
assay
materi
distribut
glass
ampoul
high
precis
reproduc
freez
dri
import
suffici
number
ampoul
prepar
provid
year
use
activ
content
remain
stabl
period
process
establish
involv
intern
collabor
studi
candid
compar
sampl
result
test
suitabl
candid
assign
provision
arbitrari
unitag
report
distribut
approv
studi
particip
eventu
approv
expert
committe
biolog
standard
ecb
prepar
storag
distribut
undertaken
nation
institut
biolog
standard
control
nibsc
south
mimm
uk
laboratori
biolog
standard
nibsc
develop
past
sever
iss
calibr
antibodi
respons
viru
vaccin
includ
iss
antibodi
dengu
hepat
viru
hav
hepat
b
viru
hbv
measl
polio
rabi
rubella
smallpox
candid
standard
human
papilloma
evalu
correspond
use
varieti
antibodi
assay
includ
viru
neutralis
vn
haemagglutinationinhibit
singl
radial
diffus
enzymelink
immunoassay
radioimmunoassay
antibodi
iss
use
epidemiolog
studi
clinic
trial
use
allow
correl
immun
potenc
requir
prophylact
therapeut
product
express
intern
unit
iu
data
sever
collabor
studi
demonstr
use
gener
reduc
level
variabl
assay
result
howev
may
problem
use
iss
due
complex
array
antibodi
popul
serum
differ
sensit
differ
assay
system
exampl
potenti
problem
found
hbv
parvoviru
studi
show
differ
assay
kit
gave
differ
result
even
includ
assay
anoth
issu
degre
antigen
homolog
viral
antigen
use
prepar
viru
use
assay
jev
collabor
studi
candid
antibodi
prepar
sera
vaccine
immun
inactiv
vaccin
antigen
differ
virus
use
vn
assay
demonstr
respons
least
inactiv
vaccin
strain
specif
candid
consequ
establish
ecb
whether
panel
monoclon
antibodi
sarscov
could
use
prepar
attract
altern
explor
signific
progress
standardis
sarscov
antibodi
assay
made
china
develop
nation
antibodi
standard
order
develop
nation
standard
sera
collect
convalesc
sar
patient
found
sarscov
vn
antibodi
titer
rang
undetect
one
serum
sampl
select
evalu
base
crossreact
four
sarscov
strain
western
blot
analysi
serum
freez
dri
ml
aliquot
assess
stabil
vn
assay
chines
standard
assign
vn
titer
confid
limit
import
develop
china
prepar
human
immunoglobulin
treatment
sar
patient
nation
guidelin
prepar
collect
plasma
qualiti
control
test
standardis
assay
three
chines
manufactur
licens
prepar
sar
immunoglobulin
sourc
materi
plasma
convalesc
patient
day
infect
good
health
plasma
test
neg
bloodborn
agent
plasma
sampl
process
combin
cold
ethanol
fraction
ultrafiltr
septemb
three
lot
igg
produc
assay
nationallyagre
procedur
stock
immunoglobulin
current
avail
suffici
treat
patient
monoclon
antibodi
yet
consid
treatment
purpos
china
import
assess
immunogen
candid
sarscov
vaccin
use
vn
assay
well
acknowledg
varieti
vn
test
use
signific
problem
sinc
time
consensu
sensit
specif
reproduc
assay
system
therefor
desir
establish
antibodi
serv
basi
comparison
vn
assay
import
activ
time
obtain
suitabl
sourc
antibodi
number
option
consid
convalesc
human
sera
postimmun
human
sera
monoclon
antibodi
hyperimmun
anim
sera
exampl
avail
suitabl
sourc
serum
convalesc
patient
hong
kong
need
explor
although
antibodi
level
individu
probabl
quit
low
also
would
import
assay
vn
includ
collabor
studi
impact
sarscov
strain
variat
examin
use
differ
sarscov
strain
andor
sera
differ
specif
central
facil
aid
reagent
cfar
base
nibsc
could
suitabl
model
sarscov
repositori
cfar
establish
support
aid
vaccin
research
eufund
current
reagent
avail
includ
peptid
recombin
protein
human
seraplasma
monoclon
polyclon
antibodi
express
system
cdna
clone
virus
comparison
drawn
sarscov
hiv
vn
assay
current
sever
differ
hiv
neutral
assay
format
consider
lack
agreement
suitabl
assay
cfar
support
joint
whoeu
project
neunet
evalu
standard
hiv
vn
assay
intern
collabor
studi
usa
sarscov
repositori
establish
behalf
american
type
cultur
collect
atcc
order
meet
need
biodef
threat
emerg
infect
type
reagent
store
includ
virus
peptid
array
monoclon
antibodi
protein
hope
activ
collabor
establish
niaid
nibsc
order
meet
expand
need
sar
research
commun
base
discuss
meet
follow
recommend
made
respect
standard
immunolog
assay
sar
vaccin
evalu
repositori
sarscov
reagent
ought
develop
collabor
niaid
nibsc
recommend
achiev
goal
consensu
must
reach
reagent
given
prioriti
repositori
need
suitabl
sourc
antibodi
convalesc
human
sera
postvaccin
human
sera
could
also
use
protocol
intern
collabor
studi
aim
valid
develop
distribut
prospect
particip
collabor
studi
particip
ask
assay
capabl
eg
number
sera
viru
strain
handl
etc
propos
collabor
studi
includ
core
set
antibodi
prepar
distribut
assay
laboratori
eg
monoclon
antibodi
anim
sera
human
sera
test
conduct
use
strain
sarscov
laboratori
differ
genet
lineag
sarscov
also
repres
studi
biosafeti
issu
associ
sarscov
vaccin
develop
stem
report
laboratoryacquir
infect
china
sanofi
pasteur
adopt
bsl
practic
bsl
equip
eg
class
microbiolog
safeti
cabinet
respiratori
protect
equip
prepar
sarscov
vaccin
note
fact
sarscov
appear
quit
resist
normal
method
viru
decontamin
jf
saluzzo
person
commun
develop
guidanc
gener
specif
handl
sar
specimen
rapid
success
develop
immunogen
protect
vaccin
sar
use
varieti
platform
encourag
temper
concern
possibl
enhanc
diseas
follow
exposur
vaccin
individu
concern
mainli
stem
report
enhanc
diseas
fipvimmun
infect
kitten
observ
antibodi
elicit
certain
coronavirus
mediat
antibodydepend
enhanc
viral
entri
observ
inflammatori
foci
liver
tissu
follow
sarscov
challeng
mvasarss
vaccin
ferret
candid
sar
vaccin
need
evalu
one
anim
model
also
need
thoroughli
evalu
durat
antibodi
respons
induc
well
breadth
protect
efficaci
differ
strain
sarscov
implic
sequenc
heterogen
among
sarscov
strain
difficult
test
time
diverg
strain
civet
sarslik
virus
recov
cultur
valid
intern
standard
immunolog
assay
evalu
candid
sar
vaccin
essenti
compar
data
across
differ
trial
requir
establish
intern
standard
sarscov
antibodi
repositori
sarscov
reagent
intern
collabor
studi
valid
iss
establish
repositori
collabor
nibsc
niaid
recommend
